Fate Therapeutics, Inc. (NASDAQ: FATE) is a Healthcare company (Biotechnology) with a market capitalization of $206M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Fate Therapeutics, Inc. had a Maz Rating of 2.77 out of 5 (C+, Hold), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.92), among the strongest in its sector; its weakest was Valuation (1.81), more expensive than most of its sector. The other factors: Financial Health 2.27 (below most of its sector); Profitability 1.93 (below most of its sector); Growth 1.85 (below most of its sector). The current rating is for members: log in to see it.
At $1.77, Fate Therapeutics, Inc. trades at 43.1x sales and 1.6x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $121M. It runs a gross margin of 38.6%, an operating margin of -2760.0% and a net margin of -2619.6%. It shows return on equity of -73.9%, return on invested capital of -62.2% and a free cash flow yield of -50.5%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 4.41. Over the past 52 weeks the share price ranged from $0.95 to $3.23, with a beta of 2.67.
Fate Therapeutics, Inc. does not currently pay a dividend.
31 Wall Street analyst ratings cover the stock: 16 Buy, 13 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.